The case for magnesium sulfate in preeclampsia-eclampsia
1992; Elsevier BV; Volume: 1; Issue: 3 Linguagem: Inglês
10.1016/0959-289x(92)90024-x
ISSN1532-3374
AutoresBaha M. Sibai, Jaya Ramanathan,
Tópico(s)Maternal and fetal healthcare
ResumoPreeclampsia-eclampsia is a syndrome of unknown etiology that is unique to human pregnancy. During the past century, numerous theories regarding its etiology have been suggested, but most have not withstood the test of time. Some of the theories that are still under consideration include abnormal placentation, cardiovascular maladaptation, immunologic intolerance between maternal and fetal tissues, genetic and dietary deficiencies. This syndrome complicates about 7% of all pregnancies; however, it remains a major cause of maternal and perinatal morbidity and mortality worldwide.’ In addition, the incidence of preeclampsia-eclampsia varies according to the population studied and the criteria used for establishing the diagnosis. The incidence is significantly increased in nulliparous women, in women with multiple gestation, and in those with previous preeclampsiaeclampsia and in women with underlying vascular or renal disease. Eclampsia is defined as the development of convulsions or coma during pregnancy or postpartum in patients with signs and symptoms of preeclampsia. In recent years the reported incidence of eclampsia ranged from 1 in 110 to 1 in 3448 pregnancies.2 The incidence reaches 3.6% in women with twin pregnancy.3 The extremely low incidence reported from some countries indicates that appropriate prenatal care, astute medical judgement, and early hospitalization of patients with preeclampsia will prevent most cases of eclampsia.2
Referência(s)